Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature

Jingjing Zhou, Dongfeng Li, Qiansong Cheng, Jingjing Zhou, Dongfeng Li, Qiansong Cheng

Abstract

Rationale: Fibrates are widely used to control hypertriglyceridemia and mixed dyslipidemia alone or in combination with statins. These drugs have rare, but severe and potentially vital adverse reactions of rhabdomyolysis and secondary acute renal failure (ARF). The objective of this article is to analyze this adverse effect of fibrates and ensure the safety of drug use.

Patient concerns: We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy.

Diagnosis: The patient was diagnosed with rhabdomyolysis associated with fenofibrate monotherapy as confirmed by symptoms of fatigue and muscle pain, and elevated levels of myoglobin and creatine kinase.

Interventions: Fenofibrate therapy was discontinued. Moreover, intravenous fluids, urinary alkalization, and diuretic were performed.

Outcomes: The symptoms were completely relieved, and relevant laboratory indexes returned to normal range during follow-up.

Lessons: Physicians should be aware of the side effect of rhabdomyolysis of fibrates, and patients should also be informed about this potential side effect, especially for patients with high-risk factors. A favorable outcome can be achieved by timely diagnosis and prompt treatment.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

References

    1. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
    1. Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C–18C.
    1. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007;19:67–73.
    1. Wang D, Wang Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. Medicine 2018;97:e0318.
    1. Wu J, Song Y, Li H, et al. Rhabdomyolysis associated with fibrate therapy review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65:1169–74.
    1. Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013;7:102–8.
    1. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159–68.
    1. Maiguma T, Fujisaki K, Itoh Y, et al. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch Pharmacol 2003;367:289–96.
    1. Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 2003;26:2482–3.
    1. Cetinkaya R, Uyanik A, Yildirim R, et al. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes. Indian J Med Sci 2008;62:458–9.
    1. Danis R, Akbulut S, Ozmen S, et al. Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case Rep Med 2010;2010.
    1. Usküdar Cansu D, Yaşar NS, Korkmaz C. Acute renal failure due to fenofibrate monotherapy. Anadolu Kardiyol Derg 2011;11:371–2.
    1. Soyoral YU, Canbaz ET, Erdur MF, et al. Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. J Pak Med Assoc 2012;62:849–51.
    1. Fujimaki S, Kuwabara T. Diabetes-induced dysfunction of mitochondria and stem cells in skeletal muscle and the nervous system. Int J Mol Sci 2017;18: pii: E2147.
    1. Pendharkar SA, Singh RG, Petrov MS. Pro-inflammatory cytokine-induced lipolysis after an episode of acute pancreatitis. Arch Physiol Biochem 2018;124:401–9.
    1. Picca A, Mankowski RT, Kamenov G, et al. Advanced age is associated with iron dyshomeostasis and mitochondrial DNA damage in human skeletal muscle. Cells 2019;8: pii: E1525.
    1. Clouâtre Y, Leblanc M, Ouimet D, et al. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 1999;14:1047–8.
    1. Ghosh B, Sengupta S, Bhattacharjee B, et al. Fenofibrate-induced myopathy. Neurol India 2004;52:268–9.
    1. Satarasinghe RL, Ramesh R, Riyaaz AA, et al. Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis-patient report and literature review. Drug Metabol Drug Interact 2007;22:279–83.
    1. Tahmaz M, Kumbasar B, Ergen K, et al. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren Fail 2007;29:927–30.
    1. Yildiz A, Gucuk E, Cay S. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy. Acta Cardiol 2008;63:515–7.
    1. Sousa AA, Kronit HS, Neves Fde A, et al. Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism. Arq Bras Endocrinol Metabol 2009;53:383–6.
    1. Kato K, Nagase A, Matsuda M, et al. Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia. Case Rep Gastroenterol 2011;5:492–6.
    1. Erdur FM, Soyoral YU, Emre H, et al. Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. Clin Biochem 2012;45:162–4.
    1. Kiskac M, Zorlu M, Cakirca M, et al. A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report. Indian J Pharmacol 2013;45:305–6.
    1. Haubenstock A, Schröcksnadel W, Bauer K, et al. Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis. Clin Chem 1984;30:1587–8.
    1. Malnick SD, Badir A, Landau Z. Bezafibrate-induced rhabdomyolysis. DICP 1991;25:869–70.
    1. Kanterewicz E, Sanmartí R, Riba J, et al. Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 1992;51:536–8.
    1. Górriz JL, Sancho A, Alcoy E, et al. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995;10:2371–2.
    1. Terrovitou CT, Milionis HJ, Elisaf MS. Acute rhabdomyolysis after bezafibrate re-exposure. Nephron 1998;78:336–7.
    1. Kamaliah MD, Sanjay LD. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 2001;42:368–72.
    1. Yang KC, Fang CC, Su TC, et al. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. Am J Kidney Dis 2005;45:e57–60.
    1. Górriz JL, Sancho A, Lopez-Martin JM, et al. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 1996;74:437–8.
    1. Atmaca H, Sayarlioglu H, Külah E, et al. Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother 2002;36:1719–21.
    1. Yen TH, Chang CT, Wu MS, et al. Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglyceridemia while receiving continuous veno-venous hemofiltration therapy. Ren Fail 2003;25:139–43.
    1. Layne RD, Sehbai AS, Stark LJ. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 2004;38:232–4.
    1. Hahn M, Sriharan K, McFarland MS. Gemfibrozil-induced myositis in a patient with normal renal function. Ann Pharmacother 2010;44:211–4.
    1. Fontaine C, Guiard-Schmid JB, Slama L, et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 2005;19:1927–8.
    1. dos Santos AG, Guardia AC, Pereira TS, et al. Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-α in liver-transplanted patients: a case report and literature review. Transplant Proc 2014;46:1887–8.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir